On this page

Alclometasone dipropionate

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Alclometasone dipropionate
Generic name
Alclometasone dipropionate
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Sun Pharmaceutical Industries, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
6
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Alclometasone Dipropionate .5 mg/g 855474 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
8

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
076587
Application type
ANDA · Abbreviated New Drug Application
Approval date
September 15, 2005
Sponsor
SUN PHARMA CANADA
Products on application
1
Submissions recorded
2
Products approved under application 076587.
Product Trade name Form Strength Ingredient Status TE Flags
076587-001 ALCLOMETASONE DIPROPIONATE CREAM ALCLOMETASONE DIPROPIONATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 076587.
Type No. Action Status Date Review
Supplement 3 Labeling Approved July 26, 2011 —
Original application 1 Approved September 15, 2005 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250729). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250729 HUMAN PRESCRIPTION DRUG · 20250709

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Alclometasone Dipropionate Cream USP, 0.05% is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see PRECAUTIONS: Pediatric Use ). Since the safety and efficacy of alclometasone dipropionate cream have not been established in pediatric patients below 1 year of age, their use in this age-group is not recommended.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Apply a thin film of alclometasone dipropionate cream to the affected skin areas two or three times daily; massage gently until the medication disappears. Alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older. Safety and effectiveness of alclometasone dipropionate cream in pediatric patients for more than 3 weeks of use have not been established. Use in pediatric patients under 1 year of age is not recommended. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Alclometasone dipropionate cream should not be used with occlusive dressings unless directed by a physician. Alclometasone dipropionate cream should not be applied in the diaper area if the child still requires diapers or plastic pants as these garments may constitute occlusive dressing. Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS ) have been treated with alclometasone dipropionate cream, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Alclometasone Dipropionate Cream USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components in this preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions have been reported with alclometasone dipropionate cream in approximately 2% of patients: itching and burning, erythema, dryness, irritation, and papular rashes. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Alclometasone Dipropionate Cream USP, 0.05% contains alclometasone dipropionate (7α-chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate), a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, alclometasone dipropionate is C28H37ClO7. It has the following structural formula: Alclometasone dipropionate has the molecular weight of 521. It is a white powder, insoluble in water, slightly soluble in propylene glycol, and moderately soluble in hexylene glycol. Each gram of alclometasone dipropionate cream contains 0.5 mg of alclometasone dipropionate in a hydrophilic, emollient cream base of Ceteth-20, cetyl alcohol, chlorocresol, glyceryl monostearate, monobasic sodium phosphate, PEG 100 stearate, phosphoric acid, propylene glycol, purified water, stearyl alcohol, and white petrolatum. Chemical Structure

OVERDOSAGE: Topically applied alclometasone dipropionate cream can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Alclometasone dipropionate cream USP, 0.05% is supplied in 15 gram tube NDC 0168-0263-15 45 gram tube NDC 0168-0263-45 60 gram tube NDC 0168-0263-60 Store between 2° and 30‐°C (36° and 86°F). E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747 I2263D R08/12 #69

Adverse event reports

Source: openFDA FAERS
309
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ALCLOMETASONE DIPROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0168-0263-15 0168-0263 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 15 g in 1 TUBE (0168-0263-15) July 12, 2005
0168-0263-45 0168-0263 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 45 g in 1 TUBE (0168-0263-45) July 12, 2005
0168-0263-60 0168-0263 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 60 g in 1 TUBE (0168-0263-60) July 12, 2005
51672-1306-1 51672-1306 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1306-1) / 15 g in 1 TUBE September 15, 2005
51672-1306-3 51672-1306 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1306-3) / 60 g in 1 TUBE September 15, 2005
51672-1306-6 51672-1306 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1306-6) / 45 g in 1 TUBE September 15, 2005
0168-0263 0168-0263 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. — July 12, 2005
51672-1306 51672-1306 Sun Pharmaceutical Industries, Inc. — September 15, 2005

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.